BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1768 related articles for article (PubMed ID: 27619566)

  • 1. CRISPR-Cas9 technology and its application in haematological disorders.
    Zhang H; McCarty N
    Br J Haematol; 2016 Oct; 175(2):208-225. PubMed ID: 27619566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic gene editing in haematological disorders with CRISPR/Cas9.
    Jensen TI; Axelgaard E; Bak RO
    Br J Haematol; 2019 Jun; 185(5):821-835. PubMed ID: 30864164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CRISPR/Cas9: an advanced tool for editing plant genomes.
    Samanta MK; Dey A; Gayen S
    Transgenic Res; 2016 Oct; 25(5):561-73. PubMed ID: 27012546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR/Cas9 Platforms for Genome Editing in Plants: Developments and Applications.
    Ma X; Zhu Q; Chen Y; Liu YG
    Mol Plant; 2016 Jul; 9(7):961-74. PubMed ID: 27108381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR/Cas9 system as an innovative genetic engineering tool: Enhancements in sequence specificity and delivery methods.
    Jo YI; Suresh B; Kim H; Ramakrishna S
    Biochim Biophys Acta; 2015 Dec; 1856(2):234-43. PubMed ID: 26434948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [CRISPR-Cas system as molecular scissors for gene therapy].
    Heinz GA; Mashreghi MF
    Z Rheumatol; 2017 Feb; 76(1):46-49. PubMed ID: 28124743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome editing using CRISPR/Cas9 to treat hereditary hematological disorders.
    Chen Y; Wen R; Yang Z; Chen Z
    Gene Ther; 2022 May; 29(5):207-216. PubMed ID: 33750926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extending CRISPR-Cas9 Technology from Genome Editing to Transcriptional Engineering in the Genus Clostridium.
    Bruder MR; Pyne ME; Moo-Young M; Chung DA; Chou CP
    Appl Environ Microbiol; 2016 Oct; 82(20):6109-6119. PubMed ID: 27496775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR/Cas9 technology as a potent molecular tool for gene therapy.
    Karimian A; Azizian K; Parsian H; Rafieian S; Shafiei-Irannejad V; Kheyrollah M; Yousefi M; Majidinia M; Yousefi B
    J Cell Physiol; 2019 Aug; 234(8):12267-12277. PubMed ID: 30697727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Application progress of CRISPR/Cas9 genome editing technology in the treatment of HIV-1 infection].
    Han Y; Li QW
    Yi Chuan; 2016 Jan; 38(1):9-16. PubMed ID: 26787519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential application and challenge of powerful CRISPR/Cas9 system in cardiovascular research.
    Li Y; Song YH; Liu B; Yu XY
    Int J Cardiol; 2017 Jan; 227():191-193. PubMed ID: 27847153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of genome editing technologies to the study and treatment of hematological disease.
    Pellagatti A; Dolatshad H; Yip BH; Valletta S; Boultwood J
    Adv Biol Regul; 2016 Jan; 60():122-134. PubMed ID: 26433620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The application of somatic CRISPR-Cas9 to conditional genome editing in Caenorhabditis elegans.
    Li W; Ou G
    Genesis; 2016 Apr; 54(4):170-81. PubMed ID: 26934570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in therapeutic CRISPR/Cas9 genome editing.
    Savić N; Schwank G
    Transl Res; 2016 Feb; 168():15-21. PubMed ID: 26470680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRISPR/Cas9 therapeutics for liver diseases.
    Aravalli RN; Steer CJ
    J Cell Biochem; 2018 Jun; 119(6):4265-4278. PubMed ID: 29266637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR/Cas9-mediated noncoding RNA editing in human cancers.
    Yang J; Meng X; Pan J; Jiang N; Zhou C; Wu Z; Gong Z
    RNA Biol; 2018 Jan; 15(1):35-43. PubMed ID: 29028415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR/Cas9, the Powerful New Genome-Editing Tool for Putative Therapeutics in Obesity.
    Franco-Tormo MJ; Salas-Crisostomo M; Rocha NB; Budde H; Machado S; Murillo-Rodríguez E
    J Mol Neurosci; 2018 May; 65(1):10-16. PubMed ID: 29732484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cas9, Cpf1 and C2c1/2/3-What's next?
    Nakade S; Yamamoto T; Sakuma T
    Bioengineered; 2017 May; 8(3):265-273. PubMed ID: 28140746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR-Cas9 therapies in experimental mouse models of cancer.
    Estêvão D; Rios Costa N; da Costa RG; Medeiros R
    Future Oncol; 2018 Aug; 14(20):2083-2095. PubMed ID: 30027767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 89.